As of 2025-12-25, the EV/EBITDA ratio of Inovio Pharmaceuticals Inc (INO) is -1.34. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. INO's latest enterprise value is 130.22 mil USD. INO's TTM EBITDA according to its financial statements is -97.48 mil USD. Dividing these 2 quantities gives us the above INO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.3x - 15.7x | 15.5x |
| Forward P/E multiples | 22.2x - 55.9x | 39.0x |
| Fair Price | (31.15) - (21.92) | (38.35) |
| Upside | -1484.3% - -1074.4% | -1804.3% |
| Date | EV/EBITDA |
| 2025-12-22 | -1.34 |
| 2025-12-19 | -1.36 |
| 2025-12-18 | -1.42 |
| 2025-12-17 | -1.58 |
| 2025-12-16 | -1.39 |
| 2025-12-15 | -1.34 |
| 2025-12-12 | -1.20 |
| 2025-12-11 | -1.25 |
| 2025-12-10 | -1.28 |
| 2025-12-09 | -1.29 |
| 2025-12-08 | -1.22 |
| 2025-12-05 | -1.21 |
| 2025-12-04 | -1.17 |
| 2025-12-03 | -1.17 |
| 2025-12-02 | -1.10 |
| 2025-12-01 | -1.10 |
| 2025-11-28 | -1.20 |
| 2025-11-26 | -1.13 |
| 2025-11-25 | -1.03 |
| 2025-11-24 | -1.03 |
| 2025-11-21 | -0.99 |
| 2025-11-20 | -0.97 |
| 2025-11-19 | -1.00 |
| 2025-11-18 | -1.08 |
| 2025-11-17 | -1.15 |
| 2025-11-14 | -1.19 |
| 2025-11-13 | -1.12 |
| 2025-11-12 | -1.13 |
| 2025-11-11 | -1.16 |
| 2025-11-10 | -1.27 |
| 2025-11-07 | -1.24 |
| 2025-11-06 | -1.34 |
| 2025-11-05 | -1.36 |
| 2025-11-04 | -1.46 |
| 2025-11-03 | -1.51 |
| 2025-10-31 | -1.41 |
| 2025-10-30 | -1.41 |
| 2025-10-29 | -1.46 |
| 2025-10-28 | -1.57 |
| 2025-10-27 | -1.51 |
| 2025-10-24 | -1.39 |
| 2025-10-23 | -1.34 |
| 2025-10-22 | -1.31 |
| 2025-10-21 | -1.39 |
| 2025-10-20 | -1.49 |
| 2025-10-17 | -1.41 |
| 2025-10-16 | -1.48 |
| 2025-10-15 | -1.54 |
| 2025-10-14 | -1.47 |
| 2025-10-13 | -1.49 |